SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice.

Hiroaki YashiroKenichi HamagamiHideyuki HiyoshiJun SugamaKazue TsuchimoriFuminari YamaguchiYusuke MoritohMinoru SasakiTsuyoshi MaekawaYukio YamadaMasanori Watanabe

Published in: Diabetes, obesity & metabolism (2019)

SCO-792 inhibited enteropeptidase in vivo, reduced food intake, decreased body weight, increased insulin sensitivity, improved glucose and lipid control, and ameliorated liver parameters in mouse models with obesity and/or diabetes. SCO-792 may exhibit similar effects in patients.

Keyphrases

type diabetes
body weight
high fat diet induced
insulin resistance
metabolic syndrome
cardiovascular disease
weight loss
end stage renal disease
glycemic control
ejection fraction
weight gain
mouse model
prognostic factors
physical activity
skeletal muscle
patient reported outcomes